MAC-Endo
Research type
Research Study
Full title
MAC-Endo: A Proof-Of-Concept and Feasibility Study of Macrophage-Targeted Immunotherapy in The Management of Endometriosis-Associated Pain
IRAS ID
1010344
Contact name
Andrew Horne
Contact email
Sponsor organisation
University of Edinburgh
Research summary
This is a study using a drug called RRx-001 for the first time in women with endometriosis. This drug has been given to over 400 cancer patients before. This study has been funded by the Chief Scientist Office and will take place in Western General Hospital and Royal Infirmary of Edinburgh. Endometriosis is a condition which affects one in ten women (or those assigned female at birth) and causes pain, infertility and can reduce quality of life. At the moment, available drug treatments have unacceptable side effects and often are hormonal meaning that they are contraceptive. There is an unmet need to find new treatments. RRx-001 has shown in pilot work that it may reduce endometriosis lesions, inflammation and therefore reduces pain. It has been given to 400 cancer patients with few side effects.
We will recruit 36 women with a diagnosis of endometriosis into the study over a period of 14 months from the gynaecology out patient department of the Royal Infirmary of Edinburgh. They will be consented and assessed for inclusion to the trial and asked to send in pain scores for four weeks and provide a biopsy from the lining of the womb. We will then carry out some further safety checks - blood tests and vital signs to ensure it is safe for the participant to be given the trial drug. Once a doctor has agreed that it is safe, the participant will be randomised (selected by chance via a computer) to have either the trial drug of a dummy drug (placebo). The drug is given via an IV infusion (directly into the patients vein in their arm) through an 'e-loop system', which takes about 15 minutes. After the drug has been given we will ask them to stay in the hospital for two hours (reducing to half an hour once after visit 2) to ensure that they have no immediate side effects. This process will be repeated over the following 5 weeks. Following treatment completion, we will then follow up the patient for 6 weeks asking about pain and quality of life questions.REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
25/WM/0075
Date of REC Opinion
24 Sep 2025
REC opinion
Further Information Favourable Opinion